Cedrus LLC Gilead Sciences, Inc. Transaction History

Cedrus LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 26, 2024	BUY	$73.27 - $83.09 $29,308 - $33,236	400 Added 9.4%	4,654 $377 Million
Q3 2023 Jan 24, 2024	SELL	$73.94 - $80.67 $46,582 - $50,822	-630 Reduced 12.9%	4,254 $319 Million
Q2 2023 Jan 24, 2024	SELL	$76.01 - $86.7 $23,183 - $26,443	-305 Reduced 5.88%	4,884 $376 Million
Q1 2023 Jan 24, 2024	BUY	$77.31 - $88.08 $19,172 - $21,843	248 Added 5.02%	5,189 $431 Million
Q4 2022 Jan 19, 2024	BUY	$62.32 - $89.47 $13,710 - $19,683	220 Added 4.66%	4,941 $424 Million
Q3 2022 Jan 19, 2024	BUY	$59.54 - $68.01 $65,732 - $75,083	1,104 Added 30.52%	4,721 $291 Million
Q2 2022 Jan 19, 2024	BUY	$57.72 - $65.01 $208,773 - $235,141	3,617 New	3,617 $224 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Cedrus LLC, based on Form 13F filings with the SEC.

Stay updated on Cedrus LLC with notifications on news.